{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:52:36Z","timestamp":1784177556299,"version":"3.55.0"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Rifamycin SV is a broad-spectrum, poorly absorbed antimicrobial agent that, when coupled with MMX technology, is being targeted for the oral treatment of traveler's diarrhea (TD) and\n            <jats:italic>Clostridium difficile<\/jats:italic>\n            -associated disease (CDAD). Rifamycin SV was tested for activity against 911 TD-associated enteropathogens and 30\n            <jats:italic>C. difficile<\/jats:italic>\n            isolates collected from several global surveillance studies. Rifamycin SV demonstrated similar antimicrobial activity levels against the\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            , with MIC\n            <jats:sub>50<\/jats:sub>\n            values ranging from 32 to 128 \u03bcg\/ml for all but one strain (an enterotoxigenic\n            <jats:italic>Escherichia coli<\/jats:italic>\n            at &gt;512 \u03bcg\/ml). For non-\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            strains, MIC\n            <jats:sub>50<\/jats:sub>\n            values ranged from 2 to 8 \u03bcg\/ml, with the exception of\n            <jats:italic>Campylobacter<\/jats:italic>\n            spp., for which all strains had MIC values of &gt;512 \u03bcg\/ml. Rifamycin SV also demonstrated excellent activity (MIC\n            <jats:sub>50<\/jats:sub>\n            of \u22640.03 \u03bcg\/ml) against most\n            <jats:italic>C. difficile<\/jats:italic>\n            strains (including one hypervirulent NAP1 strain), and this activity was even superior to the potency observed for vancomycin, metronidazole, and rifaximin. In mutational passaging studies, rifamycin SV induced stable resistance and showed a mutation frequency in\n            <jats:italic>E. coli<\/jats:italic>\n            similar to that of rifampin. This study presents the potency of rifamycin SV for enteropathogens commonly recovered from patients with TD and CDAD. Additional\n            <jats:italic>in vitro<\/jats:italic>\n            and\n            <jats:italic>in vivo<\/jats:italic>\n            studies appear necessary to determine the utility of rifamycin SV as an oral agent for the prevention and treatment of TD and CDAD.\n          <\/jats:p>","DOI":"10.1128\/aac.00688-10","type":"journal-article","created":{"date-parts":[[2010,12,14]],"date-time":"2010-12-14T04:44:21Z","timestamp":1292301861000},"page":"992-996","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["<i>In Vitro<\/i>\n            Activity and Single-Step Mutational Analysis of Rifamycin SV Tested against Enteropathogens Associated with Traveler's Diarrhea and\n            <i>Clostridium difficile<\/i>"],"prefix":"10.1128","volume":"55","author":[{"given":"David J.","family":"Farrell","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa 52317"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon D.","family":"Putnam","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa 52317"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J.","family":"Biedenbach","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa 52317"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Moro","sequence":"additional","affiliation":[{"name":"Cosmo Technologies Ltd., Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Bozzella","sequence":"additional","affiliation":[{"name":"Cosmo Research and Development, Lainate, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Celasco","sequence":"additional","affiliation":[{"name":"Cosmo Research and Development, Lainate, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa 52317"},{"name":"Tufts University School of Medicine, Boston, Massachusetts 02111"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"953","volume":"15","year":"1965","unstructured":"Bergamini, N., and G. Fowst. 1965. Rifamycin SV, a review. Arzneimittelforschung 15(Suppl.):953-1002.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/207417a0"},{"key":"e_1_3_2_4_2","unstructured":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A8 2009"},{"key":"e_1_3_2_5_2","unstructured":"Methods for antimicrobial susceptibility testing of anaerobic bacteria 2008"},{"key":"e_1_3_2_6_2","unstructured":"Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria 2006"},{"key":"e_1_3_2_7_2","unstructured":"Performance standards for antimicrobial susceptibility testing; 20th informational supplement. 2010"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K675"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2009.10.016"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.212-216.2001"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/508782"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.09.012"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2205-2206.2000"},{"key":"e_1_3_2_14_2","first-page":"841","volume":"5","year":"2009","unstructured":"Koo, H. L., H. L. Dupont, and D. B. Huang. 2009. The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea. Ther. Clin. Risk Manag. 5:841-848.","journal-title":"Ther. Clin. Risk Manag."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf044"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/524090"},{"key":"e_1_3_2_17_2","first-page":"473","volume":"59","year":"2007","unstructured":"Ruiz, J., et al. 2007. In vitro antimicrobial activity of rifaximin against enteropathogens causing travelers' diarrhea. Diagn. Microbiol. Infect. Dis. 59:473-475.","journal-title":"Infect. Dis."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn078"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_3.S402"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2009.80.609"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2006.74.1060"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.33.9.2233-2239.1995"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_3.S407"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00688-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00688-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:16:50Z","timestamp":1645485410000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00688-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1128\/AAC.00688-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.00688-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"2010-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-12-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-02-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}